Home Biosimilar Antibodies Others Antibody-Drug Conjugate Enfortumab vedotin-ejfv
For research use only. Not for use in humans.

Enfortumab vedotin-ejfv

Synonyms: Padcev

Enfortumab vedotin-ejfv (Padcev) is an antibody-drug conjugate (ADC) composed of an fully human anti-Nectin-4 IgG1 kappa monoclonal antibody (AGS-22C3), conjugated to Monomethyl Auristatin E (MMAE), via a protease-cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl. Enfortumab vedotin-ejfv has the potential for use in research of urothelial carcinoma.

Enfortumab vedotin-ejfv

CAS No. 1346452-25-2

Click to purchase products related to Enfortumab vedotin-ejfv

Quality Control

Batch: Purity: 99% Protein concentration: 7.92mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Enfortumab vedotin-ejfv (Padcev) is an antibody-drug conjugate (ADC) composed of an fully human anti-Nectin-4 IgG1 kappa monoclonal antibody (AGS-22C3), conjugated to Monomethyl Auristatin E (MMAE), via a protease-cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl. Enfortumab vedotin-ejfv has the potential for use in research of urothelial carcinoma.
References

Product Details

CAS No. 1346452-25-2
DAR 3.6
ADC antiody Enfortumab
ADC cytotoxin MMAE
Formulation 100 mM Pro-Ac, 20 mM Arg, pH 5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04724018 RECRUITING Drug: Sacituzumab Govitecan (SG)|Drug: Enfortumab vedotin-ej Urothelial Cancer; Metastatic Urothelial Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Bladder Cancer Dana-Farber Cancer Institute 2021-05-20 PHASE1; PHASE2
NCT04887870 COMPLETED Drug: Sitravatinib|Drug: Nivolumab|Drug: Pembrolizumab|Drug: Advanced or Metastatic Solid Malignancies Mirati Therapeutics Inc. 2021-06-29 PHASE2; PHASE3

(data from https://clinicaltrials.gov, updated on 2025-11-04)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.